Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing

Biogen Inc. (NASDAQ:BIIB) said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP).

Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the continued advancement of Biogen’s late-stage clinical pipeline.

In the next few years, Biogen plans to continue investing in multiple modalities and factories across the company’s two campuses in RTP.

These investments will include further expanding the antisense oligonucleotide (ASO) capabilities and infrastructure, establishing clinical and commercial multi-platform fill finish capabilities, and modernizing manufacturing technologies and controls through further advanced automation and artificial intelligence.

Also Read: Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis’ Zolgensma

“Our manufacturing footprint in the United States has played a critical role in Biogen’s history and success and in advancing the treatments … With this investment, we will modernize and expand our ...